YONGIN, South Korea, Sept. 10, 2024 /PRNewswire/ — GC Cell, a number one innovator in cell remedy, has formally introduced the execution of a landmark ‘Know-how Switch and License Settlement’ with PT Bifarma Adiluhung (Bifarma), a premier stem cell remedy firm in Indonesia. This strategic partnership, which started in June, solidifies roughly three months later with the signing of the ultimate license settlement.
Beneath the phrases of the settlement, Bifarma will likely be granted the unique rights to develop, manufacture, and commercialize Immuncell-LC for 15 years.
Bifarma is acknowledged for working Indonesia’s first GMP-certified cell remedy manufacturing facility and possesses a complete gross sales and advertising infrastructure targeted on oncology, specializing in a chilly chain distribution community that spans throughout Indonesia. This infrastructure is anticipated to maximise the accessibility and industrial success of Immuncell-LC.
James Park, CEO of GC Cell, expressed his enthusiasm concerning the partnership’s potential, stating, “The initiation of technology transfer concurrent with the signing of the license agreement sets us on a path to introduce Immuncell-LC in Indonesia by next year, leveraging both our expertise and a firm partnership with Bifarma. This milestone is pivotal as we work to introduce Immuncell-LC, South Korea’s first anticancer drug cell therapy, to a global audience, offering new treatment avenues to a broader patient demographic.”
The Indonesian pharmaceutical market, the biggest in Southeast Asia, is quickly increasing with a mean progress price exceeding 8% yearly, representing a big alternative for revolutionary remedies like Immuncell-LC. The introduction of the product is anticipated to mark a big development in Indonesia’s most cancers remedy panorama, notably for Hepatocellular Carcinoma (HCC), which impacts roughly 23,000 new sufferers yearly within the nation.
Dr. Sandy Qlintang, MBiomed., President Director of PT Bifarma Adiluhung stated, “We are excited to announce our collaboration in Immuncell-LC with GC Cell, focusing on innovative treatments for hepatocellular carcinoma (HCC) in Indonesia. By combining our expertise, we aim to enhance therapeutic strategies and bring groundbreaking advancements to liver cancer treatment through cutting-edge immune cell therapies. Together, we are committed to make a significant impact in the fight against HCC.”
Immuncell-LC, an anti-cancer immune cell remedy, has demonstrated important efficacy in stable tumors, notably liver most cancers, and has been acknowledged as an FDA-designated orphan drug. It consists primarily of autologous blood-derived T lymphocytes enhanced to enhance most cancers cell killing capabilities. The remedy has confirmed its effectiveness in large-scale Section 3 scientific trials for early-stage Hepatocellular Carcinoma (HCC) sufferers, considerably decreasing recurrence danger and mortality with a positive security profile.
As GC Cell continues to have interaction with main pharmaceutical entities throughout rising markets, the partnership with Bifarma is poised to set a precedent for the introduction of revolutionary therapies in underserved areas, promising enhanced scientific outcomes and elevated accessibility to cutting-edge remedies.
About GC Cell
With a core give attention to cell remedy, GC Cell provides full bio healthcare options from prognosis to remedy, and the model’s complete worth chain spans R&D, manufacturing, commercialization, and distribution. Extra data: https://gccell.com/
About PT Bifarma Adiluhung
PT Bifarma Adiluhung, by its cell remedy division Regenic, is Indonesia’s first and largest cell-based remedy supplier, holding GMP certification from Indonesia’s FDA and an working license from Ministry of Well being for clinical-grade manufacturing of stem cells and their metabolites. Regenic companies embody autologous and allogeneic stem cells and their derivatives, a stem cell schooling heart, and an R&D heart targeted on revolutionary cell remedy merchandise. Regenic is devoted to advancing healthcare by pioneering cell-based therapies to boost the standard of life for all people.
